Pharmacokinetics in Pediatric Patients: Drug Excretion

Newborns have markedly slower renal function compared to adults, which directly impacts drug clearance from their bodies. This reduced kidney function necessitates longer dosing intervals to prevent drug accumulation and toxicity while maintaining therapeutic concentrations. Clinicians must extend dosing frequencies for many medications to ensure safe and effective treatment in this vulnerable population.

Aminoglycoside dosing is maturity-dependent, reflecting differences in renal function between newborn populations. Term newborns typically require a 24-hour dosing interval, while preterm newborns with even slower renal function need extended intervals of 36–48 hours. This adjustment prevents drug accumulation and maintains safe therapeutic levels in preterm infants with underdeveloped kidney functions.

Drugs with high fractions excreted unchanged in urine require careful dosing frequency adjustments in pediatric patients. Without proper adjustments, these medications can accumulate in the body, leading to subtherapeutic or toxic concentrations. Maintaining appropriate drug concentrations is crucial for achieving desired therapeutic outcomes while avoiding adverse effects in children.

HIV-infected pediatric patients exhibit diverse pharmacokinetic responses that differ significantly from adults. Adult antiretroviral fixed-dose combinations may result in subtherapeutic or toxic concentrations in young patients, requiring individualized dosing adjustments. This variation underscores the necessity for tailored treatment plans based on each child's unique pharmacokinetic profile and developmental stage.

Neonates under 28 days old require a halved lamivudine dosage compared to older infants and children to accommodate their immature renal functions. While infants and children receive 4 mg/kg administered twice daily, neonates receive 2 mg/kg twice daily. This age-specific dosing adjustment reflects the critical need for developmental considerations in pediatric pharmacotherapy.

Renal maturity directly determines drug clearance rates in pediatric patients. Slower renal function in newborns and preterm infants reduces the body's ability to eliminate drugs, requiring extended dosing intervals and reduced doses. Understanding these maturity-dependent changes in renal function is essential for preventing drug accumulation and ensuring therapeutic efficacy across different pediatric age groups.

Age-specific dosing guidelines are essential because pediatric patients' underdeveloped kidney functions and varied pharmacokinetic responses differ substantially from adults. Fixed dosing regimens designed for adults may fail to achieve therapeutic targets or cause toxicity in children. Precise age-based adjustments ensure safe and effective treatment while accounting for the unique physiological characteristics of infants, children, and newborns.